Last reviewed · How we verify
YPEG-Filgrastim
At a glance
| Generic name | YPEG-Filgrastim |
|---|---|
| Sponsor | Xiamen Amoytop Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors (PHASE2)
- Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy (PHASE3)
- Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy (PHASE2)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |